Posted by AGORACOM-JC
at 9:14 AM on Thursday, December 3rd, 2020
Binovi Technologies (VISN:TSXV) is a Vision Therapy and Training Company that goes well beyond fixing eyes that simply can’t read letters on an eye chart. That’s what your optometrist does when they prescribe glasses.
What Binovi does is far more exciting and groundbreaking. Without getting scientific, Binovi delivers higher performing brains by optimizing the performance of your eyes. The result is a faster brain through stronger eyes, which creates quite the edge for the world’s best athletes and explains why their client list includes:
Dallas Stars (NHL)
Chicago Cubs (MLB)
Sporting KC (MLS)
Tennis Canada
Showcased During NFL Scouting Combine
Eli Wilson Goaltending – The World Leader In Hockey Goaltending Development
BUT EXECUTIVE CHAIRMAN, TERRY BOOTH, HAS A DIFFERENT AND BIGGER VISION (PARDON THE PUN) FOR BINOVI – GLOBAL CHILDREN
When Terry’s daughter was 5 years old, she developed eye problems that could only be treated by patching – something he says would be considered “barbaric” today. Terry discovered that 1 in 4 kids (not a typo) have vision problems beyond those treatable by an optometrist. This was a global, epidemic without a solution that often leads to kids losing critical learning time and self-confidence by Grade 3.
Fast Forward 30 years and Terry finally found the solution – Binovi – but not before he and his science team put CEO Adam Cegielski and the Company through the ringer. When the due diligence was complete, Terry Booth was all in with ~ $500,000 of his own money now invested, plus more from his network. Most importantly, he’s bringing his entire science, government and finance network to the table to bring Binvoi to children around the world.
Turn off NetFlix. Ignore your social media notifications. Grab your favourite beverage, call a couple of friends and watch this interview … twice.
Can’t spare enough time to stare at a screen? Take AGORACOM with you in your car or on your walk by Podcast on Apple, Google, Spotify or your favourite podcaster.
Posted by AGORACOM-JC
at 2:09 PM on Friday, November 20th, 2020
(VISN:TSXV) (EYCCF:OTCQB) (2EYA:GR)
Trusted and used by some of the world’s top professional sports teams, including:
BINOVI PLATFORM
Quicky becoming an industry standard in the sports performance enhancement and vision rehabilitation markets
Allows clinicians to track patient progress remotely, reviewing profiles at any time, and assigning new and updated treatment plans that update in Binovi Coach in real time
Integrated multi-media instructions allow patients to accurately follow their prescribed activities from home as normal, while the included secure messaging allows for communication between patients and their care teams to answer any questions and provide updates
In addition, resources in Binovi Academy, part of Binovi Pro, are available to clinicians looking to broaden their knowledge base
State-of-the-art platform which measures 14 key vision skills that are essential for maximizing brain performance.
Used by professional sports teams and has been tested by more than 1,500 vision performance professionals in over 20 countries
BINOVI TOUCH
THE MARKET OPPORTUNITY
Vision Therapy captures 3% of a $36B Yearly Vision Market today
Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022
Posted by AGORACOM-JC
at 6:45 PM on Tuesday, November 17th, 2020
Closed its previously announced non-brokered private placement financing for gross proceeds of $2,050,000
The Company issued a total of 16,078,431 units at $0.1275 per unit, with each unit comprised of one common share of the Company and one common share purchase warrant
TORONTO, ON and NEW YORK, NY / November 17, 2020 /Binovi Technologies Corp., (Binovi) (TSXV:VISN)(OTCQB:BNVIF), a leader in neuro-vision performance technology, is pleased to announce it has closed its previously announced non-brokered private placement financing for gross proceeds of $2,050,000 (the “Private Placement”). The Company issued a total of 16,078,431 units at $0.1275 per unit, with each unit comprised of one common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Share (each, a “Warrant Share”) at an exercise price of $0.40 per Warrant Share at any time until November 16, 2022. The warrants are subject to an acceleration clause whereby if the common share price is equal to or greater than $0.45 for a period of 5 consecutive trading days (at any time at or following the expiry of the four months resale restriction period), the Company may, by notice to the warrant holder reduce the remaining exercise period applicable to the warrants to not less than 30 days from the date of such notice.
The Company paid aggregate finder’s fees of $21,274.65 in cash and 166,860 finder’s warrants, with each finder warrant having the same terms as the Warrants.
The securities issued in connection with the Private Placement are subject to a four-month hold period expiring on March 18, 2021. Further restrictions may apply to certain subscribers under foreign securities laws.
Insiders participated in the Private Placement acquiring an aggregate of 2,284,314 units on the same basis as other subscribers. The participation in the Private Placement by insiders of the Company constitutes a “related party transaction” as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on exemptions from the formal valuation and minority approval requirements under MI 61-101. The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as the fair market value of the private placement in so far as the private placement involved interested parties did not exceed 25% of the Company’s market capitalization.
The Company intends to use the net proceeds from the Private Placement for general working capital.
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 9:39 AM on Tuesday, November 17th, 2020
Announced the appointment of Dr. Susan Barry to the Binovi Scientific Advisory Board. Dr. Barry joins the other members of the board in directing the company’s advancements
“Dr. Barry’s experiences as a patient of vision therapy have informed her extensive career and we hope to gain from her perspective on both sides of the vision care coin. Her work in the neurological examination of vision will prove incredibly valuable in our pursuit of further testing and treatment options for students and patients young and old,” commented Adam Cegielski, President and CEO.
November 17, 2020 Toronto, New York – Binovi Technologies Corp., (Binovi) (TSXV:VISN ) ( OTC:BNVIF) is proud to announce the appointment of Dr. Susan Barry to the Binovi Scientific Advisory Board. Dr. Barry joins the other members of the board in directing the company’s advancements.
“Dr. Barry’s experiences as a patient of vision therapy have informed her extensive career and we hope to gain from her perspective on both sides of the vision care coin. Her work in the neurological examination of vision will prove incredibly valuable in our pursuit of further testing and treatment options for students and patients young and old,” commented Adam Cegielski, President and CEO.
“It is a distinct privilege to have Dr. Barry join our Scientific Advisory Board,” said Dr. Leonard Press, Chief Scientific Officer. “Her unique blend of insights and communication skills that crosses many lines between educators, eyecare professionals, researchers and the public is a tremendous asset to Binovi.”
” Children struggling in school, adults recovering from a stroke, and athletes seeking to improve their game may all benefit from vision therapy. Its effects are often life-changing. I am looking forward to working with the Binovi team to develop new training techniques, explore the science behind vision therapy, and make vision therapy more accessible worldwide,” commented Dr. Susan R Barry, Ph.D.
About Dr. Susan Barry
Susan R. Barry, Ph.D. is an educator, scientist, and author who has spoken worldwide on the topics of neuroplasticity and binocular vision. She earned her B.A. in biology from Wesleyan University in 1976 and Ph.D. in biology from Princeton University in 1981. She has worked as a research neuroscientist at the University of Miami Medical School, the University of Michigan, the Marine Biological Laboratory, and NASA’s Johnson Space Center and published papers on synaptic transmission and eye-head-hand coordination. In 1992, she joined the faculty of Mount Holyoke College where she rose to the rank of full professor, retiring from the college in 2016. The Princeton Review lists Barry among the 300 outstanding college teachers in the U.S., her paper on the work of Frederick W. Brock was selected as the best published paper in the Journal of Behavioral Optometry in 2011, and in 2013 she received the Meribeth E. Cameron Faculty Award for Scholarship from Mount Holyoke College.
For years, Barry taught her neurobiology students the conventional scientific wisdom that stereovision could develop only during a critical period in early childhood. She even used her own vision history to support this dogma since she had been cross-eyed since early infancy and was stereoblind. However, at age forty-eight, she consulted a developmental optometrist who prescribed a program of optometric vision therapy. To her utter astonishment, her vision improved dramatically, and she experienced her first 3D views. Dubbed “Stereo Sue” by Oliver Sacks in a 2006 New Yorker article by that name, Dr. Barry has gone on to write her own book Fixing My Gaze: A Scientist’s Journey into Seeing in Three Dimensions (Basic Books, 2009) which was rated the fourth best science book for 2009 by the editors of Amazon.com, selected as one of the best sci-tech books of 2009 by the Library Journal, and has been translated into seven languages. Barry’s second book, Coming to Our Senses: A Boy Who Learned to See, A Girl Who Learned to Hear, and How We All Discover the World , will be published by Basic Books in the summer of 2021.
Binovi is a best-in-class neuro-visual platform designed to test, analyze, track, and report on individual vision and cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Sports Performance testing and training, and other areas of specialized care. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Posted by AGORACOM-JC
at 7:08 PM on Thursday, November 5th, 2020
Further to the private placement that closed on October 6, 2020, the Company plans to complete an additional non-brokered private placement financing for gross proceeds of up to $2,000,000, expected to close the week of November 9, 2020
The Private Placement will consist of up to 15,686,275 units at $0.1275 per unit, subject to the approval of the TSXV Venture Exchange. Each unit will be comprised of one common share and one share purchase warrant.
Toronto, New York – November 5, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN ) | ( OTCQB:BNVIF), a leader in neuro-vision performance technology, announces that further to the private placement that closed on October 6, 2020, the Company plans to complete an additional non-brokered private placement financing (the “Private Placement”) for gross proceeds of up to $2,000,000, expected to close the week of November 9, 2020. The Private Placement will consist of up to 15,686,275 units at $0.1275 per unit, subject to the approval of the TSXV Venture Exchange. Each unit will be comprised of one common share and one share purchase warrant. Each warrant entitles the holder to acquire a further common share at a price of $0.40 per share for a period of 24 months, subject to an acceleration clause.
The Company intends to use the net proceeds from the Private Placement for general working capital. All securities to be issued pursuant to the Private Placement are subject to a four-month hold period under applicable securities laws in Canada.
AGORACOM Agreement
Further to its news release dated April 28, 2020, the Company announces, it will make its third issuance of shares under its online marketing and awareness program with Agora Internet Relations Corp. (“AGORACOM”). Pursuant to this third tranche, the Company will issue 104,308 common shares of the Company at a deemed price of $0.13 subject to a hold period expiring February 7, 2021. AGORACOM’s program includes a “CEO Verified” Discussion Forum. The forum serves as the Company’s primary social media platform to interact with both shareholders and the broader investment community in a fully moderated environment.
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
